@article{0ff63ae36eb14e7b9ca7938f713b46db,
title = "The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis",
keywords = "JAKARTA, JAKARTA2, Metabolic effects, Ruxolitinib, Weight gain",
author = "Douglas Tremblay and Lara Cavalli and Oumar Sy and Shelonitda Rose and John Mascarenhas",
note = "Funding Information: We thank the patients and families who made these trials possible. The original trials were supported by Sanofi S.A.; this reanalysis was funded by Bristol Myers Squibb. All authors contributed to and approved the manuscript; writing and editorial assistance were provided by Brian Kaiser and Sheila Truten of MEDCOMCO, funded by Bristol Myers Squibb.",
year = "2022",
month = jul,
doi = "10.1016/j.clml.2022.01.003",
language = "English",
volume = "22",
pages = "e463--e466",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Elsevier Inc.",
number = "7",
}